Dragonfly's novel cytokines and TriNKET™ NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.
February 6, 2023
Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine
Dragonfly now wholly owns the IL12 cytokine, currently in mid-Phase 1 dose escalation as a monotherapy and in combination with nivolumab....